Candel therapeutics announces upcoming presentations at the 2024 asco annual meeting

Needham, mass., april 25, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that two abstracts were accepted for presentation at the 2024 american society of clinical oncology (asco) annual meeting taking place may 31 to june 4, 2024, in chicago, il. the first presentation will feature data from the ongoing phase 1 clinical trial of can-3110 in patients with recurrent high-grade glioma. the presentation will focus on patients recruited in cohort c, treated with multiple injections of can-3110 (up to six), demonstrating that this approach is both feasible and well tolerated. the second presentation will show topline overall survival data from the phase 2 clinical trial of can-2409 plus valacyclovir, in combination with continued immune checkpoint inhibitor (ici) treatment in patients with non-resectable, stage iii/iv non-small cell lung cancer (nsclc) who have an inadequate response to front line anti-pd(l)1 therapy.
CADL Ratings Summary
CADL Quant Ranking